ExpreS2ion Biotech (One-pager): Market value below cash balance

Multitude has returned to profitable growth after a few difficult years, and we expect the company to continue on this path in the coming years. In view of this, we consider the valuation to be low and the risk/reward of the stock to be attractive.

Petri Gostowski, Co-Head of Research, gives an introduction to the Helsinki Stock Exchange.

Growth in early December was entirely driven by strong online sales growth.

Uppesittarkväll är ett av Sveriges mest omtyckta program för dig som är aktie- och sparintresserad. Under två timmar väntar vi tillsammans in lönen. Det närmar sig jul. Vi hjälps åt med julrim och snackar som vanligt aktier och julcase!

Yesterday, GomSpace announced its new 2025 guidance, implying expectations of a revenue growth rate above 30%, EBITDA margin between -2% and +10%, and a positive free cash flow. Following the new guidance for 2025, we have updated our investment case one-pager, including an updated overview of the peer group.

The fourth part of our series of articles focusing on investing in Life Science companies deals with value creation in drug development companies through M&As and licensing agreements.

Yesterday, GomSpace released its new 2025 guidance ranges, with midrange showing expectations of solid revenue growth and positive EBITDA margin. Moreover, the company expects positive free cash flow. As a result, the company is entering a new phase after a period of focusing on stabilizing the business and making it profitable. This was also one of the themes we touched on during our event yesterday with GomSpace's CEO Carsten Drachmann.

Together with ExpreS2ion Biotechnologies' CEO, Bent Frandsen, we looked back at the main achievements in 2024, which was the first year of implementing the new strategy. The company has focused on leveraging the platform to advance assets with shorter development timelines, and it has also been a year with good progress in the pipeline. In the interview, you can hear more about the progress of the breast cancer candidate, external validation through partnerships, and lastly which milestones investors should look out for in 2025.

Arni Ekholm, CEO, talks about vehicle aftermarket consolidator Relais as an investment.

Den första analysen av Spotify är publicerad, och vi sammanfattar huvudpunkterna tillsammans med analytiker Christoffer. Vi djupdyker i vad som driver utvecklingen för streamingjätten, hur bolaget väntas vända från negativa resultat till lönsamhet under 2024 och vilka långsiktiga mål som ligger i sikte för Spotify.